Treatment of alcohol dependence: Recent progress and reduction of consumption

Minerva Medica

Volumn 105, Issue 6, 2014, Pages 447-466

  Testino, G ^a   Leone, S ^b   Borro, P ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Alcohol dependence; Nalmefene; Reduction

Indexed keywords

ACAMPROSATE; ARIPIPRAZOLE; BACLOFEN; DISULFIRAM; FLUPENTIXOL; FLUVOXAMINE; GABAPENTIN; METADOXINE; NALMEFENE; NALTREXONE; NEUROSTEROID; ONDANSETRON; OXCARBAZEPINE; OXYBATE SODIUM; PRAZOSIN; PREGABALIN; QUETIAPINE; SERTRALINE; TOPIRAMATE; VALPROIC ACID; VARENICLINE; VIGABATRIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DRUGS USED IN THE TREATMENT OF ADDICTION; NEW DRUG; TAURINE;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; BINGE DRINKING; CHRONIC DISEASE; COMBINATION CHEMOTHERAPY; CONFUSION; DECREASED APPETITE; DIZZINESS; DRUG APPROVAL; ETHICS; FAMILY CONFLICT; FATIGUE; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HEALTH CARE COST; HUMAN; INSOMNIA; LIVER DISEASE; LIVER TOXICITY; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PSYCHOSOCIAL CARE; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; TRAFFIC ACCIDENT; VIOLENCE; VOMITING; ALCOHOL-RELATED DISORDERS; ANALOGS AND DERIVATIVES; CLASSIFICATION; CONTRAINDICATIONS; DRUG EFFECTS; EUROPE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); ONSET AGE; PHYSIOLOGY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); WITHDRAWAL SYNDROME;

AGE OF ONSET; ALCOHOL DETERRENTS; ALCOHOL-RELATED DISORDERS; ALCOHOLISM; BINGE DRINKING; CRAVING; DISULFIRAM; DRUGS, INVESTIGATIONAL; EUROPE; HUMANS; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; NALTREXONE; NEUROTRANSMITTER AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM OXYBATE; TAURINE;

EID: 84924922412     PISSN: 00264806     EISSN: 18271669     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. Rehm J, Zatonksi W, Taylor B, Anderson P. Epidemiology and alcohol policy in Europe. Addiction 2011;106(Suppl 1):11-9.
2. Testino G. Alcoholic diseases in hepato-gastroenterology: a point of view. Hepato-Gastroenterol 2008;55:371-7.
3. Boffetta P, Hashibe M, La Vecchia C. The burden of cancer attributable to alcohol drinking. In J Cancer 2006;119:884-7.
4. Schutze M, Boeing H, Pishon T. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ, online first, bmj.com, 2011
5. Cloninger CR, Bohman M, Sigvardsson S. Inheritance of alcohol abuse. Cross-fostering analysis of adopted men. Arch Gen Psych 1981;38:861-8.
6. Babor TF, Hofmann MI, Del Boca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rousaville B. Types of alcoholics. Evidence for an empirically derived typology based on indicator of vulnerability and severity. Arch Gen Psychiatry 1992;49:599-608.
7. Lesh OM, Dietezel M, Musalek M, Walter H, Zeiler K. The course of alcoholism. Long term prognosis in different subtypes. Forensic Scint 1988;36:121-38.
8. Addolorato G, Mirijello A. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013;27:287-99.
9. Singleton EG, Henningfield JE, Tiffany ST. Alcohol craving questionnaire: ACQ-now: background and administration manual. Baltimore: NIDA Addiction Research Centre; 1994.
10. Love A, James D, Willmer P. A comparison of two alcohol craving questionnaires. Addiction 1998;93:1091-2.
11. Statham DJ, Connor JP, Kavanagh DJ, Feeney GF, Young RM, May J, Andrade L. Measuring alcohol craving: development of the alcohol craving experience questionnaire. Addiction 2011;106:1230-8.
12. Verheul R, Van Den Brink W, Geerlings P. A three pathway psychobiological model of craving for alcohol. Alcohol Alcohol 1999;34:197-222.
13. Martinotti G, Di Nicola M, Tedeschi D, Callea A, Di Giannantonio M, Janiri L; CravingStudy Group. Craving typology questionnaire: a scale for alcohol craving in normal controls and alcoholics. Comprehensive Psychiatry 2013;54:925-32.
14. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM. Combined pharmacotherapies and behavioural interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295:2003-17.
15. O'Malley SS, O'Connor PG. Medications for unhealthy alcohol use. Alcohol Res Health 2011;33:300-12.
16. European Medicine Agency. This EPAR was last updated on February 4, 2014. [cited 2014 September 12]. Available from: http://www.ema.europa.eu/ema
17. Caputo F, Vignoli T, Grignaschi A, Cibin M, Addolorato G, Bernardi M. Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond. EurNeuropsychopharmacol 2013; http://dx.doi.org/10.10l6/j.euroneuro.2013.10.004
18. Franck J, Jayaram-Lindstrom J. Pharmacotherapy for alcohol dependence: status of current treatments. Current Opinion in Neurobiology 2013;23:692-9.
19. Addolorato G, Leggio L, Ferrulli A, Caputo F, Gasbarrini G. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opinlnvestig Drugs 2009;18:1-22.
20. Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochreane Database Syst Rev 2010;2:CD006266.
21. Caputo F, Francini S, Stoppo M, Lorenzini F, Vignoli T, Del Re A et al. Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. J Psychopharmacol 2009;23:883-90.
22. Caputo F, Francini S, Brambilla R, Vigna-Taglianti F, Stoppo M, Del Re A et al. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. EurNeuropsychopharmacol 2011;21:450-6.
23. Addolorato G, Caputo F, Leggio L, Vignoli T, Abenavoli L, Lorenzini F et al. Gamma hydroxybutyric acid (GHB) withdrawal does not occur at therapeutic dosage. Drug Alcohol Depend 2005;77:209.
24. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate. CNS Drugs 2005;19:517-37.
25. Rossetti ZL, Carboni S. Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur J Pharmacol 1995;283:177-83..
26. Dahchour A, De Wittte P, Bolo N, Nedelec JF, Muzet M, Durbin P, Macher JP. Central effects of acamprosate blocks the glutamate increase in the nucleoaccumbensmicrodialysate in ethanol withdrawn rats. Psychiatry Res 1998;82:107-14.
27. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol dependent individuals: results and meta-analysis. Alcohol Clin Exp Res 2004;28:51-63.
28. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006;40:383-93.
29. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al. COMBINE study research group: Combined pharmacotherapies and behavioural interventions of alcohol dependence - the Combine study: a randomized controlled trial. J Am Med Assoc 2006;295:2003-17.
30. Mann K, Lemenager T, Hoffmann S, Reinhard I, Hermann D, Batra A et al the PREDICT Study Team. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol 2013;18:937-46.
31. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2012; CD004332.
32. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013;108:275-93.
33. Verheul R, Lehert P, Geerlings PJ, Koeter MW, Van Den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl) 2005;178:167-73.
34. Tolliver BK, De Santis SM, Brown DG, Prisciandaro JJ, Brady KT. A randomized, double-blind, placebocontrolled clinical trial of acamprosate in alcoholdependent individuals with bipolar disorder: a preliminary report. Bipolar Disorders 2012;14:54-63.
35. Tek C, Srihari V, Tek E. Successful acamprosate treatment of alcohol dependence in schizophrenia. Schizophrenia Research 2008;106:373.
36. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 2012;3:497-508.
37. Kiefer F, Witt SH, Frank J, Richter A, Treutlein J, Lemenager T et al. Involvement of the atrial natriuretic peptide transcriptor factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 2011;11:368-74.
38. Karpyak VM, Winham SJ, Biernacka JM, Cunningham JM, Lewis KA, Geske JR et al. Association of GATA4 sequence variation alcohol dependence. Addict Biol 2014;19:312-5.
39. Stromberg MF, Mackler SA. A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited access procedure in rats. PharmacolBiochemBehav 2002;72:483-90.
40. Lee MC, Wager HN Jr. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988;29:1207-11.
41. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010;8:CD001867.
42. Oslin DW, Berrettini W, Kranzler HR. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcoholdependent patients. Neuropsychopharmacology 2003;28:1546-52.
43. Anton R. Naltrexone for the management of alcohol dependence. N Engl J Med 2008;359:715-21.
44. Marini V, Fucile C, Zuccoli ML, Testino G, Sumberaz A, Robbiano L et al. Involvement of the mu-opioid recepto gene polymorphism A118G in the efficacy of detoxification of alcohol dependent patients. Addictive Behaviors 2013;38:1669-71.
45. Volpicelli JR, Rhines KC, Rhines JS. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997;54:737-42.
46. Bartus RT, Emerich DF, Hotz J. Vivitrex, an injectable extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamics evidence of efficacy for 1 month in rats. Neuropsychopharmacology 2003;28:1973-82.
47. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997;28:5-24.
48. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004;28:1051-9.
49. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study. Lancet 2007;370:1915-20.
50. Muzyk AJ, Rivelli SK, Gagliardi JP. Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence. CNS Drugs 2012;26:69-78.
51. Addolorato G, Caputo F, Capristo E. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002;37:504-8.
52. Dore GM, Lo K, Juckes L, Bezyan S, Latt N. Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series. Alcohol Alcohol 2011;46:714-20.
53. Caputo F, Vassallo G, Pappas G, Grignaschi A, Bernardi M, Zoli G, Addolorato G. Pharmacological treatment of alcoholdependence. Alcologia 2012;14:1120.
54. Johnson BA, Ait-Daud N, Bowden CL, Diclemente CC, Roache JD, Lawson K et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003;361:1677-85.
55. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Bey-Ers K et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007;298:1641-51.
56. Amini M, Runyon BA. Alcoholic hepatitis: a clinician's guide to diagnosis and therapy. World J Gastroenterol 2010;16:4905-12.
57. Addolorato G, Mirijello A, Leggio L, Ferrulli A, Landolfi R. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013;27:287-99.
58. Calabrese V, Bombaci G, Calderone A, Rizza V. Effects of metadoxine on cellular free fatty acid levels in ethanol treated rats. Int J Tiss React 1993;15:235-43.
59. Shpilenya LS, Muzychenco AP, Gasbarrini G, Addolorato G. Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebo-controlled study. Alcohol Clin Exp Res 2002;26:340-6.
60. Diaz Martinez MC, Diaz Martinez A, Villamil Salcedo V, Cruz Fuentes C. Efficacy of metadoxine in the management of acute alcohol intoxication. J Int Med Res 2002;30:44-51.
61. Leggio L, Kenna GA, Ferrulli A, Zywiak WH, Caputo F, Swift RM et al. Preliminary findings of metadoxine for the treatment of alcohol dependence and alcoholic disease. Hum Hum Psychopharmacol Clin Exp 2011;26:554-9.
62. Keating GM. Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs 2013;27:761-72.
63. European Medicines Agency. Selincro (nalmefene): EU summary of product characteristics, 2013. http://files.sharehoIder.com/downloads/AMDA-GCCOO/2 4705573427x0x655042/6278cfbf543d-49f5-86ad be 78a2fd4fe/Selincro%First%20 Lauchees.pdf
64. Ingman K, Hagelberg N, Alto S. Prolonged central micron-opioid receptor occupancy after single and related nalmefene dosing. Neuropsychopharmacology 2005;30:2245-53.
65. Kissler JL, Sirohi S, Reis DJ. The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors. Biol Psychiatry 2014;75:774-82
66. Fudala PJ, Heishman SJ, Henningfield JE. Human pharmacology and abuse potential nalmefene. Clin Pharmacol Ther 1991;49:300-6.
67. Mann K, Bladstrom A, Troup L. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 2013;73:706-13.
68. Gual A, He Y, Torup L. A randomized, double-blind, placebo controlled efficacy study of nalmefene, asneeded use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013;23:1432-42.
69. Sinclair J, Chick J, Sorensen P, Kiefer F, Batel P, Gual A. Can alcohol dependent patients adhere to an "as-needed" medication regimen? Eur Addict Res 2014;20:209-17.
70. Van Den Brink W, Sorensen P, Torup L, Mann K, Gual A for the SENSE Study Group. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomized controlled study. J Psychopharmacol 2014;28:733-44.
71. Van Den Brink W, Aubin HJ, Baldstrom A. Efficacy of as needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol 2013;48:570-8c.
72. Des Spence D. Bad medicine: nalmefene in alcohol misuse. BMJ 2014;348:1531.
73. Nalmefene for alcohol dependence. BMJ 2014;52:54-7.
74. European Medicine Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence. 2010. [cited 2014 September 12]. Available from: http:/www.ema.europa.eu/docs/en-LIBRARY/Scientific-guideline/2010/03/WC500074898.pdf
75. Soderpalm B, De Bejczy A, Ericson M, Guterstam J, Hammarberg A, Franck J et al. The ethanol nAChR interaction and its relevance for modulating ethanol consumption in rodents and man. Alcohol Clin Exp Res 2012; S202.
76. Mitcell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) 2012;223:299-306.
77. Litten RZ, Ryan CH, Ferting JB, Falk DE, Johnson B, Dunn KE et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 2013 [Epub ahead of print].
78. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Field HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology 2012;223:299-306.
79. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn EK et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 2013;7:277-86.
80. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 2005;19:873-96.
81. Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 2014;171:445-52.
82. Johnson BA, Roache JD, Javors MA, Diclemente CC, Cloninger CR, Prihoda IJ et al. Ondasentron for reduction of drinking among biologically predisposed alcoholic patients. A randomized controlled trial. JAMA 2000;284:963-71.
83. Johnson BA. Medication treatment of different types of alcoholism. Am J Psychiatry 2010;167:630-9
84. Mason BJ, Quello S, Goodell V, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence. A randomized clinical trial. JAMA Intern Med 2014;174:70-7.
85. Caputo F, Bernardi M. Medications acting on the GABA system in the treatment of alcohol dependence: a review. Curr Pharm Des 2011;17:1323-32.
86. Curzio O, Tilli A, Mezzasalma L. Characteristics of alcoholics attending "clubs of alcoholics in treatment" in Italy: a national survey. Alcohol Alcohol 2012;47:317-21.
87. Testino G, Borro P. Liver transplantation and severe acute alcoholic hepatitis: an ethical consideration. J Hepatol 2014;61:706-7.
88. Testino G, Leone S, Sumberaz A, Borro P. Liver transplantation in alcoholic patients. Alcohol Clin Exp Res 2014;38:1800-2.
89. Mathurin P, Deltenre P. Effect of binge drinking on the liver: an alarming public health issue? Gut 2014;58:613-7.
90. McCarty CA, Ebel BE, Garrison MM. Continuity of binge and harmful drinking from late adolescence to early adulthood. Pediatrics 2004;114:714-9.
91. Rolland B, Karila L, Guardia D, Cottencin O. Pharmacological approaches of binge drinking. Current Pharmaceutical Design 2011;17:1333-42.
92. Crews FT, Boettiger CA. Impulsivity, frontal lobes and risk for addiction. Pharmacol Biochem Behav 2009;93:237-47.
93. Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res 2000;24:737-42.
94. Ait-Daoud N, Johnson BA, Prihoda TJ, Hargita ID. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacol 2001;154:23-7.
95. Anton RF, Myrich H, Wright TM, Latham PK, Baros AM, Waid LR et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 2011;168:709-17.
96. Batki SL, Pennington DL. Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. Am J Psychiatry 2014;4:391-4.
97. Aubin HJ, Daeppen JB. Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption. Drug and Alcohol Dependence 2013;133:15-29.
98. Gastfriend DR, Garbutt JC, Pettinati HM, Forman RF. Reduction in heavy drinking as a treatment outcome in alcohol dependence. Journal Substance Abuse Treatment 2007;33:71-80.
99. World Health Organization, 2007. WHO expert committee on problems related to alcohol consumption [cited 2014 September 12]. Available from: http://www.who.int/substance.abuse/expert
100. Volpicelli JR, Alterman Al, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-80.
101. Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liv Inter 2003;23:45-53.
102. Verrill C, Markham H, Templeton A. Alcohol-related cirrhosis early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 2009;104:768-74.
103. Pezzilli R. Pancreatic stellate cells and chronic alcoholic pancreatitis. JOP 2007;8:254-7.
104. Addolorato G, Mirijello A, Leggio L. Alcohol addiction: toward a patient-oriented pharmacological treatment. Expert Opin Pharmacother 2013;14:2157-60.
105. Testino G, Sumberaz A, Borro P. Liver transplantation for patients with alcoholic liver disease: an open question. Dig Liver Dis 2013;45:80-1.